A BETAMI-DANBLOCK sub-study found higher erectile dysfunction odds at three months, but no later association or significant overall IIEF-score effect.
In a European Heart Journal conference-supplement abstract published on 2026-10-26, BETAMI-DANBLOCK investigators reported higher odds of erectile dysfunction among men assigned beta-blockers at three months. The association was not present at later follow-ups. Researchers also found no statistically significant treatment effect on men's overall IIEF sexual-function scores.
The investigators described the male finding as small and temporary. That makes this a more specific result than a broad claim that beta-blockers either cause erectile dysfunction or have no sexual effects. The distinction between a questionnaire's overall score and its erectile-dysfunction threshold is central to understanding the update.
For people recovering from a heart attack, the practical relevance is a conversation about sexual changes during medication review. The study supports taking those concerns seriously without assuming that a prescription explains every change.
The research was a prespecified sexual-function sub-study within BETAMI-DANBLOCK. It compared treatment groups among people enrolled in the parent trial after myocardial infarction, the medical term for a heart attack.
The analysis assessed participants who reported sexual activity within the previous year. Participants had an LVEF of at least 40%. LVEF is a measure of heart function.
Sexual-function assessments took place at baseline and at three, 12, and 21 months. This repeated schedule allowed investigators to examine whether differences between treatment groups appeared at one assessment or remained evident over time.
For men, the analysis considered overall IIEF scores and whether participants met the study's threshold for erectile dysfunction. These outcomes describe related aspects of sexual function, but they are not interchangeable. One is a score considered across the questionnaire; the other identifies whether a score meets a defined cutoff.
This design matters because the headline finding concerns the threshold outcome at the first follow-up. It should be read alongside the overall score results and the later assessments, rather than in isolation.
According to the European Heart Journal abstract, men in the beta-blocker group had higher odds of meeting the erectile-dysfunction threshold at three months. The researchers did not find that association at subsequent follow-ups.
At the same time, beta-blocker treatment had no statistically significant effect on men's overall IIEF scores during follow-up. Both results belong in an accurate account of the study.
A threshold divides results into categories. An overall score captures a broader measurement. A difference in the odds of crossing a cutoff is therefore not the same finding as a statistically significant difference in the overall score.
This helps explain why the results are not contradictory. The study found an early difference in one way of classifying erectile function without finding a significant treatment effect on the overall questionnaire score.
The timing also matters. Describing only the three-month result would leave out the later findings. Describing only the later findings would overlook the early difference that investigators reported.
A balanced summary is straightforward: the sub-study found a temporary association with erectile-dysfunction classification among men. It did not find a statistically significant treatment effect on their overall IIEF scores. Neither result should be substituted for the other when discussing what the research showed.
The published work is a conference-supplement abstract rather than a full research paper. The page also states that the table referenced in the abstract is not included in the available text. This limits scrutiny of the detailed results and reporting.
Participation is another consideration. Only 82% of the sexually active subgroup completed at least one follow-up questionnaire. The findings do not describe people who were not sexually active or those who did not complete an assessment.
The heart-function eligibility criteria also narrow the population covered. Results should not automatically be extended to people with more reduced heart function. This is not a finding about every person recovering from a heart attack.
The abstract reports an association within this trial population. It does not establish beta-blockers as the sole cause of any participant's erectile difficulties. It also does not establish why the early association was absent at later assessments.
Likewise, a result that is not statistically significant does not prove that no individual experienced a medication-related change. Group findings and individual experiences answer different questions.
For women, investigators reported no effect on FSFI scores but described the estimates as uncertain. Those findings should not be treated as equivalent to the male results or as firm reassurance about effects in women.
The sexual-function findings sit within a broader cardiovascular research programme. A separate BETAMI-DANBLOCK sub-study published in the European Heart Journal examined cardiovascular hospitalisation after myocardial infarction. Its stated focus was a different outcome from the sexual-function measures discussed here.
That distinction is useful. A question about a possible sexual side effect is not the same as a question about cardiovascular outcomes. A medication review needs to consider the reason for treatment as well as concerns that arise during its use.
The EAU guideline chapter on managing erectile dysfunction addresses the wider clinical subject of erectile concerns. By comparison, this abstract contributes a specific finding from a defined post-heart-attack trial population. It does not supply a new treatment pathway.
For readers considering erectile concerns within a broader health assessment, this is the important connection: a sexual-function result adds information to care rather than settling every question about it.
The update is therefore best understood as a contribution to an existing discussion. It gives clinicians and patients a particular early finding to consider without replacing the wider assessment of cardiovascular treatment or erectile difficulties.
The practical message is to include sexual function in post-heart-attack medication reviews. New or worsening erectile difficulties can be discussed with the care team alongside questions about recovery and treatment.
The research supports asking whether medication, recovery or other factors could be involved. It does not support stopping or changing a prescribed beta-blocker without medical advice. The sub-study did not test self-directed medication changes.
A useful discussion can begin with a description of what changed rather than a conclusion about its cause. Details that may help include:
These are practical conversation prompts, not a study-tested protocol. They keep the discussion grounded in the person's experience while leaving individual assessment to qualified care.
The distinction between timing and cause is especially important. Noticing a change after starting a medicine provides information for the review. It is not, by itself, a complete explanation of why the change occurred.
Similarly, the study's later group results are not a personal timetable for recovery. They should not be read as a promise that an individual's concern will disappear at a particular point.
For someone unsure how to put the experience into words, describing the pattern of erectile difficulties offers a starting point for discussion. The aim is not to assign blame to a medicine or to dismiss the concern because a group average looks reassuring.
Sexual wellbeing can have a place in the recovery conversation without becoming a test of whether recovery is going well. A change in sexual function deserves room in that story, without becoming the whole story.
Deciding how to interpret an erectile change during heart attack recovery calls for context, where Sexential's role is education rather than medication decisions. For adults aged 35 to 65 concerned about confidence after changing sexual experiences, its evidence-aware coverage connects sexual function with everyday wellbeing while keeping general information separate from personalised medical advice.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A large menopause analysis has sparked debate about the timing of biological change. Understand the evidence and its limits for sexual wellbeing.
A review links breast reduction with higher sexual-function scores. Read the findings, study limits and questions to bring to a clinician.
A large Flo app survey found different links between solo orgasms, partnered orgasms and satisfaction. Read the findings and their limits for midlife.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
